Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Open-label, Phase 2 Study of Imprime PGG and Pembrolizumab in Subjects With Advanced Melanoma Failing Front-line Treatment With Checkpoint Inhibitors (CPI) or TNBC Failing Front-line Chemotherapy for Metastatic Disease

NCT02981303 is registered in ClinicalTrials.gov with HiberCell, Inc. as lead sponsor.

NCT NCT02981303
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02981303 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Open-label, Phase 2 Study of Imprime PGG and Pembrolizumab in Subjects With Advanced Melanoma Failing Front-line Treatment With Checkpoint Inhibitors (CPI) or TNBC Failing Front-line Chemotherapy for Metastatic Disease
Lead sponsor
HiberCell, Inc.
Phase
Phase 2
Overall status
Completed
Start date
February 22, 2017
Completion date
December 31, 2020
Enrollment
64 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

advanced melanoma, triple-negative breast cancer